ArticleERJ open research2025
Longer term post-hospital morbidity and mortality following admission with COVID-19: a systematic review and meta-analysis.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Post-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up.Journal of clinical medicine · 2026Review
- Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study.Nature communications · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The acute mortality and morbidity associated with COVID-19 are well recognised, but the longer-term consequences for patients who survive hospitalisation are less clear. This systematic review aims to establish the longer-term (90 days or beyond) readmission and all-cause mortality outcomes of adult patients discharged after an index hospital admission with COVID-19. Methods: The systematic review was registered with PROSPERO (CRD42021253290) and reported according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Five databases were searched on 7 May 2024 for studies in English: Medline, Embase, Scopus, Web of Science and Global Health. Two reviewers independently screened studies and assessed eligibility. Risk of bias assessments were undertaken using ROBINS-E, funnel plots and Egger's test. The GRADE framework was used to evaluate the evidence quality. Data were pooled using a random-effects model with sensitivity and subgroup analyses. Results: Of 339 studies screened for morbidity, 39 were included (295 892 patients). Meta-analysis showed readmission frequency was 12% (95% CI 9-16%) at 90+ days (range 3-22 months). Of 5831 studies screened for mortality, 56 were included (176 920 patients). The post-hospital all-cause mortality was 5% (95% CI 4-6%) at 90+ days (range 3-36 months). Heterogeneity and risk of bias were generally high, with possible publication bias, resulting in GRADE evidence quality being very low. Conclusions: Patients who survive an index hospital admission with COVID-19 remain at longer-term risk of hospital readmission and/or death following discharge, which has implications for healthcare resource allocation and planning, and the search for interventions to reduce chronic complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.